{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T20:03:04Z","timestamp":1764187384635,"version":"3.46.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.7759\/cureus.97878","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:59:27Z","timestamp":1764187167000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Dupilumab-Associated Ocular Surface Disease in the Paediatric Population"],"prefix":"10.7759","author":[{"given":"Vivien","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/0115748871263396231121060901","article-title":"Potential indications of dupilumab in Th-2 inflammatory disease","volume":"19","author":"Ilaria P","year":"2024","unstructured":"Ilaria P, Nevena S, Ersilia T, et al.. Potential indications of dupilumab in Th-2 inflammatory disease. Rev Recent Clin Trials. 2024, 19:53-61. 10.2174\/0115748871263396231121060901","journal-title":"Rev Recent Clin Trials"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri G","year":"2019","unstructured":"Agnihotri G, Shi K, Lio PA. A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis. Drugs R D. 2019, 19:311-8. 10.1007\/s40268-019-00288-x","journal-title":"Drugs R D"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade B","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al.. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019, 181:459-73. 10.1111\/bjd.17869","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00742-w","article-title":"Baseline demographics and severity and burden of atopic dermatitis in adult patients initiating dupilumab treatment in a real-world registry (PROSE)","volume":"12","author":"Bagel J","year":"2022","unstructured":"Bagel J, Nguyen TQ, Lima H, et al.. Baseline demographics and severity and burden of atopic dermatitis in adult patients initiating dupilumab treatment in a real-world registry (PROSE). Dermatol Ther (Heidelb). 2022, 12:1417-30. 10.1007\/s13555-022-00742-w","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner A","year":"2021","unstructured":"Bohner A, Topham C, Strunck J, et al.. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea. 2021, 40:584-9. 10.1097\/ICO.0000000000002461","journal-title":"Cornea"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister AD","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018, 154:1208-11. 10.1001\/jamadermatol.2018.2690","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70025","article-title":"Dupilumab-associated ocular surface disease in paediatric atopic dermatitis patients: results from the BioDay Registry","volume":"55","author":"van der Rijst LP","year":"2025","unstructured":"van der Rijst LP, van Luijk CM, van der Kamp S, Zuithoff NP, de Boer JH, de Bruin-Weller MS, de Graaf M. Dupilumab-associated ocular surface disease in paediatric atopic dermatitis patients: results from the BioDay Registry. Clin Exp Allergy. 2025, 55:391-402. 10.1111\/cea.70025","journal-title":"Clin Exp Allergy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041031","article-title":"Association between dupilumab and conjunctivitis: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Lin TY","year":"2023","unstructured":"Lin TY, Wang CY, Wang FY, Kang EY, Hwang YS. Association between dupilumab and conjunctivitis: a systematic review and meta-analysis of randomized controlled trials. Pharmaceutics. 2023, 15:1031. 10.3390\/pharmaceutics15041031","journal-title":"Pharmaceutics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13924","article-title":"Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting","volume":"63","author":"Foley P","year":"2022","unstructured":"Foley P, Kerdraon YA, Hogden JP, et al.. Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting. Australas J Dermatol. 2022, 63:421-36. 10.1111\/ajd.13924","journal-title":"Australas J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.02.002","article-title":"Dupilumab-associated ocular manifestations: a review of clinical presentations and management","volume":"67","author":"Wu D","year":"2022","unstructured":"Wu D, Daniel BS, Lai AJ, et al.. Dupilumab-associated ocular manifestations: a review of clinical presentations and management. Surv Ophthalmol. 2022, 67:1419-42. 10.1016\/j.survophthal.2022.02.002","journal-title":"Surv Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2460578","article-title":"Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study","volume":"36","author":"Rob F","year":"2025","unstructured":"Rob F, Pinkova B, Sokolova K, Kopuleta J, Jiraskova Zakostelska Z, Cadova J. Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study. J Dermatolog Treat. 2025, 36:2460578. 10.1080\/09546634.2025.2460578","journal-title":"J Dermatolog Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index-a practical guide","volume":"33","author":"Hanifin JM","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index-a practical guide. Dermatitis. 2022, 33:187-92. 10.1097\/DER.0000000000000895","journal-title":"Dermatitis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet A","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran TH. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019, 8:485-90. 10.1007\/s40123-019-0191-9","journal-title":"Ophthalmol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1711010","article-title":"Punctal stenosis associated with dupilumab therapy for atopic dermatitis","volume":"32","author":"Lee DH","year":"2021","unstructured":"Lee DH, Cohen LM, Yoon MK, Tao JP. Punctal stenosis associated with dupilumab therapy for atopic dermatitis. J Dermatolog Treat. 2021, 32:737-40. 10.1080\/09546634.2019.1711010","journal-title":"J Dermatolog Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123104","article-title":"Dupilumab-associated blepharoconjunctivitis: clinical and morphological aspects","volume":"11","author":"Serino F","year":"2023","unstructured":"Serino F, Dattilo V, Cennamo M, et al.. Dupilumab-associated blepharoconjunctivitis: clinical and morphological aspects. Biomedicines. 2023, 11:3104. 10.3390\/biomedicines11123104","journal-title":"Biomedicines"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela MZ","year":"2021","unstructured":"Popiela MZ, Barbara R, Turnbull AM, et al.. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond). 2021, 35:3277-84. 10.1038\/s41433-020-01379-9","journal-title":"Eye (Lond)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad259.039","article-title":"dupilumab-associated ocular surface disease in children with eczema in a tertiary paediatric hospital in London","volume":"189","author":"Rampersad A","year":"2023","unstructured":"Rampersad A, Gholam K, Solman L, Cartledge N, Gore S, Petrof G. P31 Eyeing up: dupilumab-associated ocular surface disease in children with eczema in a tertiary paediatric hospital in London. British J Dermatol. 2023, 189:52-3. 10.1093\/bjd\/ljad259.039","journal-title":"British J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18141","article-title":"Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience","volume":"36","author":"Stingeni L","year":"2022","unstructured":"Stingeni L, Bianchi L, Antonelli E, et al.. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022, 36:1292-9. 10.1111\/jdv.18141","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.042","article-title":"Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis","volume":"9","author":"Achten R","year":"2021","unstructured":"Achten R, Bakker D, Ariens L, et al.. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021, 9:1389-1392.e2. 10.1016\/j.jaip.2020.09.042","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.12.003","article-title":"Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids","volume":"117","author":"Thorne JE","year":"2010","unstructured":"Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010, 117:1436-41. 10.1016\/j.ophtha.2009.12.003","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437759-clinical-outcomes-of-dupilumab-associated-ocular-surface-disease-in-the-paediatric-population","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:59:28Z","timestamp":1764187168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437759-clinical-outcomes-of-dupilumab-associated-ocular-surface-disease-in-the-paediatric-population"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.97878","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}